In this month’s episode of the Scope of Things, host Deborah Borfitz covers the latest news and emerging trends, including the launch of a company using single-solution software to connect a global network of clinical trial sites to study sponsors, a pharmacy-first program in the UK, a centralized staffing initiative at the National Cancer Institute, progress in getting patient-derived organoids into clinical trials to evaluate drug response, and more. She also speaks with Lifelines Neuro’s chief scientific officer Dona Murphey, M.D., Ph.D. about shortcomings in the way EEGs are being use in clinical trials to monitor participants with potential brain damage, how EEG monitoring should be used in clinical research, and what the FDA has to say about all of this.
Show Notes
News Roundup
Launch of Pi Health
Pharmacy First initiative in the UK
Pediatric rare disease research
- Article in Hepatology about utility of real-world cohort
NCI Virtual Clinical Trials Office
Precision oncology clinical trial landscape
Translational Research Innovation Program
Patient-derived organoids in clinical trials
- Study in Cells Tissues Organs
Guest
Dona Murphey, M.D., Ph.D., chief scientific officer for Lifelines Neuro
Dona is a neurologist, neuroscientist, historian of science, and community health worker educated at Harvard and Baylor College of Medicine. She currently serves as principal consultant at In Phase Neuro and fractional chief scientific officer at Synthesys Brain Health (a joint endeavor between Lifelines Neuro and Neurovative Diagnostics), specializing in the area of EEG in clinical trials.